EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer

Aaron P Mitchell iD, Andrew Salner iD, Paul Palyca, Azeez Farooki, Sonia Persaud iD, Nirjhar Chakraborty iD, Dedipya Bhamidipati iD, Maria Klimchuk iD, Michaela A Dinan iD, Michael S Leapman iD, Allison Lipitz-Snyderman iD, Anis Hamid iD und 2 weitere

JCO Oncology Practice · 2026

DOI: 10.1200/op-25-00457 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Aaron P Mitchell und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bone Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oncology clinical practice guidelines recommend bone-modifying agents (BMAs) to decrease skeletal-related events for patients with metastatic castration-resistant prostate cancer (mCRPC) and against BMAs to decrease skeletal-related events in metastatic castration-sensitive prostate cancer (mCSPC). Previous studies have identified gaps in guideline-concordant BMA use, but interprovider variation is poorly understood. METHODS We conducted a multicenter, retrospective, cohort study of patients diagnosed with prostate cancer and bone metastases during 2020-2021. The sample included three health systems in the Northeastern United States: two community-based networks and one academic cancer center. Patient characteristics and BMA use (zoledronic acid and denosumab) were ascertained via chart review. The outcomes of interest were BMA overuse during castration-sensitive prostate cancer (CSPC; defined as BMA initiation before emergence of castration-resistant prostate cancer [CRPC], among patients without a comorbid condition for which BMA therapy may be appropriate: osteoporosis, osteopenia, or osteoporotic fracture) and appropriate use during CRPC (BMA initiation after emergence of CRPC). RESULTS There were 153 eligible patients, 51 from each health system. At diagnosis, 14 (9%) patients had documented osteoporosis or osteopenia, 22 (14%) had previous osteoporotic fracture, and 36 (24%) had chronic renal insufficiency. Among 95 patients assessable for overuse during CSPC, 16% (n = 17) received BMA (ranging from 13% to 21% among the three systems). Among 55 patients who developed CRPC, 44% (n = 24) had initiated BMA therapy as of most recent follow-up. There was greater variation in use during CRPC, ranging from 22% to 54% across the three systems. CONCLUSION BMA overuse in mCSPC was rare, potentially reflecting de-implementation following evidence of lack of benefit. Appropriate BMA use for patients with mCRPC varies substantially among clinicians and health care systems. Interventions to increase guideline-concordant care may improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsBone NeoplasmsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedRetrospective Studies

Substanzen

Bone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Weill Cornell Medicine, New York, NY.
  • Hartford HealthCare Cancer Institute, Hartford, CT.
  • Lehigh Valley Health Network, Lehigh Valley Topper Cancer Institute, Allentown, PA.
  • Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Aaron P Mitchell, Andrew Salner, Sonia Persaud, Nirjhar Chakraborty, Dedipya Bhamidipati, Maria Klimchuk, Michaela A Dinan, Michael S Leapman, Allison Lipitz-Snyderman, Anis Hamid, Jamie S Ostroff, Michael J Morris

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Mitchell, A. P., Salner, A., Palyca, P., Farooki, A., Persaud, S., Chakraborty, N., Bhamidipati, D., Klimchuk, M., Dinan, M. A., Leapman, M. S., Lipitz-Snyderman, A., Hamid, A., Ostroff, J. S., & Morris, M. J. (2026). Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer. JCO Oncology Practice. https://doi.org/10.1200/op-25-00457

Vancouver

Mitchell AP, Salner A, Palyca P, Farooki A, Persaud S, Chakraborty N, et al. Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer. JCO Oncology Practice. 2026. doi:10.1200/op-25-00457

BibTeX
@article{Mitchell2026,
  author = {Mitchell, Aaron P and Salner, Andrew and Palyca, Paul and Farooki, Azeez and Persaud, Sonia and Chakraborty, Nirjhar and Bhamidipati, Dedipya and Klimchuk, Maria and Dinan, Michaela A and Leapman, Michael S and Lipitz-Snyderman, Allison and Hamid, Anis and Ostroff, Jamie S and Morris, Michael J},
  title = {Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-00457}
}
Kostenlos starten →